Anti-GBM disease is a vasculitis affecting glomerular and/or pulmonary capillaries (Goodpasture syndrome – GP). The tissue damage is mediated by anti-GBM antibodies that recognize an antigen located on the glomerular (and alveolar) basement membrane, inducing a marked inflammatory response.
The prevalence of anti-GBM antibodies in patients with renal involvement is about 60%, increasing to 80–90% in patients with pulmonary involvement. Approximately 10% of patients present both antibodies.
If left untreated, GP syndrome has an unfavourable prognosis. Early diagnosis is therefore critical for survival and for the recovery of renal function. The diagnosis can be supported by the detection of anti-GBM antibodies.
As the titre correlates with disease activity, regular quantitative measurements of antibody titres should be performed to monitor the success of the treatment.
Serum, EDTA plasma, heparin plasma*, citrate plasma
*immunoblot test only
Immunoblot, ChLIA
Fasting for at least 8-12 hours before sampling
Refer to the Health Service Charter to check storage conditions
+2/+8°C
This test provides the quantitative determination of total tau protein to support the diagnosis of Alzheimer’s disease.
This test provides the quantitative determination of tau protein phosphorylated at threonine 181 (pTau181), to support the diagnosis of Alzheimer’s disease.
Test for the determination of human autoantibodies against NMDAR to support the diagnosis of paraneoplastic neurological syndromes with an intermediate-risk phenotype.
Subscribe to our newsletter to be always updated.